Lymphoma Hub | Quarter Four 2020 Update

The Lymphoma Hub strives to inform real-world clinical practice by providing the latest trial and drug updates, key literature, and congress coverage.

In the last quarter of 2020, due to the current COVID-19 pandemic, the Lymphoma Hub continued to carry out all functions in a virtual setting including the attendance of key conferences —the European School of Haematology (ESH) 2nd How to Diagnose and Treat: Lymphoma, and the 62nd American Society Hematology (ASH) Annual Meeting and Exposition— where we provided live coverage via our Twitter channel, conducted interviews with experts, and published summary articles of key sessions and podcasts.

During the ESH 2nd How to Diagnose and Treat: Lymphoma conference, the Lymphoma Hub also hosted a virtual Satellite Symposium, where five international experts —Gilles Salles, Kieron Dunleavy, Marie-José Kersten, Astrid Pavlovsky, and Francesc Bosch— discussed the management and treatment of patients with relapsed/refractory lymphoma. The symposium was attended by 124 participants, spanning over 35 countries and was also made available on-demand. The talks were also made available as summary articles on the Lymphoma Hub with downloadable slides.

In October, the Lymphoma Hub introduced a new educational theme of the “Mutational profile and treatment of Waldenström’s macroglobulinemia”. Through articles and expert interviews, the Lymphoma Hub has been providing expanded information to advance knowledge on this important topic.

Furthermore, on October 20, the Lymphoma Hub held a virtual Steering Committee (SC) meeting. Scientific Education Support presented the recent highlights and achievements of the Lymphoma Hub, including the successful delivery of the satellite symposium, improving all metrics on the website and social media platforms, and continuing to be a top social media influencer at all major congresses. The SC provided guidance and insights on relevant topics and current challenges in lymphoma and chronic lymphocytic leukemia, as well as suggestions on how to address the current unmet educational needs.

The Lymphoma Hub, founded in partnership with the European Lymphoma Institute and brought to you by Scientific Education Support, is dedicated to providing up-to-date, independent material for healthcare professionals. The Lymphoma Hub would like to thank our existing platinum supporter BMS, gold supporters Roche/Genentech and Incyte, silver supporters Gilead and Novartis, bronze supporters Nordic Nanovector, and our contributors Epizyme and Karyopharm Therapeutics —without whom the platform would not be possible.

For more information on the Lymphoma Hub, please visit lymphomahub.com. For media enquiries, or to explore collaboration opportunities, please contact